8-K: Synaptogenix Secures $5 Million in Financing to Fuel Growth and Acquisitions

Synaptogenix, a biopharmaceutical company, has announced a $5 million financing agreement with existing investors through a combination of a registered offering and a private placement.

Summary

• Synaptogenix has secured $5 million in funding through the sale of 5,000 shares of Series C convertible preferred stock.
• The financing includes a registered public offering and a concurrent private placement.
• The preferred stock has a stated value of $1,000 per share and is convertible into common stock at an initial price of $4.00 per share.
• The preferred stock accrues a 5% quarterly dividend payable in cash.
• Warrants to purchase common stock are also included, with an initial exercise price of $4.00 per share, exercisable immediately for a term of five years.
• The company intends to use the net proceeds for general corporate purposes, including research and development, clinical trials, capital expenditures, and working capital.
• The offering is expected to close on or about September 12, 2024, subject to customary closing conditions.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the successful financing and its intended use. However, there are some risks and negative aspects associated with the financing, such as potential dilution and covenants, which temper the overall sentiment.

Positives

• The financing provides Synaptogenix with additional capital to pursue strategic opportunities.
• The company has secured the support of committed long-term investors.
• The funds will support research and development efforts and potential acquisitions.
• The company has a large safety data base from previous Bryostatin-1 cancer studies.

Negatives

• The conversion of preferred stock and exercise of warrants could dilute existing shareholders.
• The company is subject to certain affirmative and negative covenants regarding the incurrence of indebtedness, acquisitions, and other transactions.

Risks

• The company's ability to settle conversions is subject to certain limitations, including a limit on the number of shares that may be issued until stockholder approval is obtained.
• The company is required to redeem the Series C Preferred Shares in equal quarterly installments, commencing on October 31, 2024, which may impact cash flow.
• The company is subject to certain affirmative and negative covenants regarding the incurrence of indebtedness, acquisitions, and other transactions.
• The company may be obligated to pay liquidated damages to investors if it fails to file the resale registration statement or maintain its effectiveness.
• The company's ability to settle conversions is subject to certain limitations set forth in the Certificate of Designations, including a limit on the number of shares that may be issued until the time, if any, that the company's stockholders have approved the issuance of more than 19.99% of the company's outstanding shares of Common Stock in accordance with Nasdaq listing standards.

Future Outlook

The company expects to use the net proceeds from the Offering for general corporate purposes, including research and development expenses, clinical trial expenses, capital expenditures, and working capital. The company also intends to explore potential acquisitions.

Management Comments

• We are pleased to benefit from the support of our committed long-term investors in this financing, said Dr. Alan Tuchman, Chief Executive Officer of Synaptogenix.
• This capital enhances our ability to be both strategic and opportunistic as we explore potential acquisitions or fund research on innovative assets, all with the goal of driving growth and maximizing value for our shareholders.

Industry Context

This financing is a common strategy for biopharmaceutical companies to raise capital for research and development, clinical trials, and potential acquisitions. The company's focus on neurodegenerative disorders aligns with the growing interest and investment in this area.

Comparison to Industry Standards

• The terms of the financing, including the conversion price, dividend rate, and warrant terms, are within the typical range for similar transactions in the biopharmaceutical industry.
• The use of a combination of a registered offering and a private placement is a common approach for companies seeking to raise capital efficiently.
• The company's focus on neurodegenerative diseases is consistent with the industry's focus on addressing unmet medical needs in this area.
• The company's stated intention to use the funds for research and development, clinical trials, and potential acquisitions is a typical strategy for biopharmaceutical companies.

Stakeholder Impact

• Shareholders may experience dilution due to the conversion of preferred stock and exercise of warrants.
• Employees may benefit from the company's increased financial stability and ability to fund research and development.
• Customers may benefit from the company's ability to develop new therapies for neurodegenerative diseases.
• Creditors may benefit from the company's improved financial position.

Next Steps

• The company expects to close the offering on or about September 12, 2024.
• The company will file a final prospectus supplement with the SEC.
• The company will seek stockholder approval for the issuance of more than 19.99% of the company's outstanding shares of Common Stock.
• The company will use the net proceeds for general corporate purposes, including research and development, clinical trials, capital expenditures, and working capital.
• The company will explore potential acquisitions.

Key Dates

Keywords

financing, convertible preferred stock, warrants, biopharmaceutical, neurodegenerative disorders, registered offering, private placement, capital raise, Bryostatin-1, clinical trials